Background: Angiosarcomas are a rare but aggressive form of soft tissue sarcoma. At metastatic stage, the clinical benefit of therapeutic intervention remains debatable.
introduction
Angiosarcomas account <2%-3% of adult soft tissue sarcoma [1] [2] [3] [4] [5] . Angiosarcomas display remarkable clinical heterogeneity in term of presentation and behavior. These tumors can occur in any location of the body (two-thirds are cutaneous, mainly in head and neck area, one-fourth arise in soft tissue) [6, 7] . The known risk factors are some hereditary predisposing syndromes (such as Recklinghausen's disease), occupational exposure to arsenical insecticide or to polyvinyl chloride, chronic lymphedema whatever its cause and almost prior radiation therapy [3, [6] [7] [8] [9] .
Angiosarcomas ideally require medical attention from a knowledgeable multidisciplinary medical team. The cornerstone of the treatment is a large en bloc resection [6, 7, [10] [11] [12] [13] [14] followed as much as possible by adjuvant radiation therapy [14] . There is no consistent data supporting the administration of adjuvant chemotherapy for this tumor, despite the fact that up to 50% of angiosarcomas develop distant metastasis [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] . With this high rate of metastatic relapse, angiosarcomas constitute one of the most aggressive subtypes of soft tissue sarcomas.
At metastatic stage, by analogy with other histological subtypes of soft tissue sarcomas, the classical treatment is based on doxorubicin-containing regimen [6, 7] . Nevertheless, the available evidence is very spare: 19 cases reported by Fury et al. [6] and 17 cases reported by Fayette et al. [7] . Furthermore, some retrospective studies [6, [17] [18] [19] and one phase II trial [20] suggest that weekly paclitaxel should be considered as a valuable alternative option for metastatic angiosarcoma. Nevertheless, it is difficult to infer these promising results to the daily practice and the role of chemotherapy remains debatable.
Regarding the relative rarity of such disease, a randomized trial (doxorubicin-based regimens versus weekly paclitaxel or versus palliative care) seems to be hardly feasible. So, we have carried out a retrospective analysis to identify prognostic factors at metastatic stage and to better determine the activity of both doxorubicin-based regimens and weekly paclitaxel as front-line treatment.
patients and methods patients One hundred and forty nine patients with metastatic angiosarcoma who had been treated in 14 French Sarcoma Centers between August 1996 and December 2009 were included in this retrospective study.
collected parameters
The following parameters have been collected: gender, age, presence of known hereditary predisposing condition, presence of predisposing lymphedema, angiosarcoma arising in irradiated fields, treatment given for the primary angiosarcoma, Fédération Nationale Centre le Cancer grade [2] , presence of epithelioid differentiation, presence of metastatasis at initial diagnosis (versus metachronous metastasis), date of metastatic relapse, primary location, presence of bone metastasis, presence of pulmonary metastasis, presence of liver metastasis, presence of other metastasis, controlled primary at the time of metastasis diagnosis, performance status and different biological parameters (lymphocyte count, hemoglobin level, albumin level, increasing in lactate dehydrogenase-LDH-level, increasing in alkaline phosphatase level and increasing in liver transaminases). We have also collected the nature of systemic treatment given as first-line, the response to this treatments and the time to progression. Some patients underwent surgery for the residual disease after chemotherapy; this data was also collected.
general description of the patients and treatments
The main characteristics of the patients have been described in the whole cohort and for the four following groups: patients treated by exclusive palliative care (absence of systemic treatment), patients treated with doxorubicin-based regimens, patients treated with weekly paclitaxel and patients treated with other regimen. For these four categories, we have also calculated the median overall survival (Kaplan-Meier method and log-rank test), the median time to progression (Kaplan-Meier method and log-rank test) and the repartition of the best-reported objective responses.
identification of prognostic factors
The primary end point was overall survival time (from the date of metastasis diagnosis to the death). Patients who were alive at the last followup visit were censored. The univariate analysis was based on Kaplan-Meier method and log-rank test. The 26 in skin (including scalp and face in 12 cases), 11 in liver, 9 in heart, 7 in pleura, 7 in spleen, 4 in bone, 4 in kidney and 2 in lung. In four cases of polymetastatic angiosarcoma, the primary was not identified. The rarest primary locations were (one case/location): aorta, pulmonary artery, colon, hypophysis, mediastinum, ovary, thyroid and bladder. The median size of the primary was 8 cm (range 1-25 cm). About 62% of angiosarcomas were grade 3 tumors. The primary had been treated by surgery in 76 cases (51.0%, including 44 R0, 13 R1 and 29 R2 resections), by adjuvant chemotherapy in 32 cases (21.4%) and adjuvant radiotherapy in 22 cases (14.7%). In the end of this local treatment, the primary angiosarcoma had been considered controlled in only 51 cases (34.3%).
metastatic disease
Metastases have been diagnosed at initial diagnosis in most cases (62%, 86/139). At the time of metastatic disease, the baseline characteristics have been described in Tables 1 and 2 . The treatment included chemotherapy in 134 cases (89.9%).
The chemotherapy regimens were doxorubicin-containing regimens in 70 cases, weekly paclitaxel in 47 cases and other regimens in 16 cases (sorafenib in 4 cases, cisplatin plus vinorelbine in 2 cases, carboplatin plus etoposide in 2 cases and one case of the following regimens: carboplatin alone, cisplatin alone, dacarbazine, ifosfamide, vinorelbine, vinblastine, chlorambucil and metronomic cyclophosphamide). The median overall survival was 2.2 months in absence of chemotherapy, 9.7 months with the miscellaneous regimens, 11.0 months with the doxorubicin-containing regimens and 13.1 months with weekly paclitaxel (P = 0.0092). The median time to progression was 3.2 months with the miscellaneous regimens, 3.9 months with the doxorubicin-containing regimens and 5.6 months with weekly paclitaxel (P < 0.001). The best objective responses were reported in the Table 3 . The tumor control (objective response plus stable disease) was significantly better with weekly paclitaxel and doxorubicincontaining regimens compared with the miscellaneous regimens (P < 0.001), but there was no statistically significant difference in terms of overall survival between weekly paclitaxel and doxorubicin-based regimens (P = 0.81).
The treatment included surgery in eight cases (5.4%, Table 4 ). The median overall survival of this subgroup of patients was not reached.
prognostic factor analysis
The median follow-up was 9.0 months (range 0.2-125.0 months). One hundred and sixteen patients died at the last follow-up. The median overall survival was 11.3 months. The univariate analysis retained the following poor prognostic factors: presence of bone metastasis (P = 0.0107), presence of other metastasis (P = 0.0327), a performance status of two or more (P < 0.0001), low level of hemoglobin (P = 0.006), low level of albumin (P = 0.006) and increasing in LDH level (P < 0.0001). The Cox model analysis retained only one independent prognostic factor: performance status two or more (hazard ratio [HR] = 2.49 [1.61-3.85], P < 0.0001; see Figure 1 ).
impact of the respective treatments
After adjustment to the performance status, the following treatments significantly improved the outcome: doxorubicincontaining regimens (HR = 0.38, P = 0.0165; Figure 2 ), weekly paclitaxel (HR = 0.36, P = 0.0146; Figure 2 ) and metastasectomy (HR = 0.09, P = 0.0221; Figure 3 ) ( Table 5 ). The respective impacts of doxorubicin-containing regimens and weekly paclitaxel were similar (Figure 3) . On the contrary, other systemic treatments did not influence the outcome compared with exclusive palliative care (P = 0.5339).
discussion
The key findings of this retrospective study could be summarized as follows: (i) the median overall survival of patients with metastatic angiosarcoma is 11 months, (ii) at metastatic stage, performance status is the main prognostic factor (iii) doxorubicin-based regimen and weekly paclitaxel Annals of Oncology original articles seem to provide a similar impact on the outcome and (iv) metastasectomy is associated with a major improvement of overall survival. Characteristics of the present series are consistent with literature data. The female predominance is well established [6, 7, 12, s15] . The reported median age is 52-62 years [6, 7, 12, 15] . About 25% of angiosarcomas are of low grade [7] . The primary distribution widely varies across the different series [6-8, 10-12, 14-16] . The median overall survival of patients with metastatic angiosarcoma is 8-12 months [7, 12] .
Some prognostic factors have been described at localized stage: the tumor size (with a threshold set at 5 cm in most cases) [8, 11, [14] [15] [16] , the grade [6, 7, 13, 15, 16] and the margin status [6, 7, 13] . But until now, there is no identified prognostic factor for metastatic angiosarcomas. The major prognostic value of performance status in metastatic angiosarcoma is not surprising; performance status is a well-known prognostic factor of metastatic soft tissue sarcoma in general [21] [22] [23] . In the present series, metastatic angiosarcoma arising in irradiated fields had the same outcome than de novo angiosarcoma. In the Vorburger and the Fury series [6, 16] , the prognosis of primary breast angiosarcoma and the chest wall angiosarcoma arising in irradiated fields are quite similar . In our experience, visceral angiosarcomas seem to be associated with poor outcome (median overall survival of 9 months compared with 13 months for 'superficial' angiosarcoma); but this difference does not reach the level of significance.
Doxorubicin is the backbone of chemotherapy in patients with locally advanced or metastatic soft tissue sarcoma, with the exceptions of some particular entities now better treated by molecular targeted therapies (such as gastrointestinal stromal tumors or dermatofibrosarcomas). Doxorubicin remains the best single agent with proven activity, providing a median overall survival of 8-14 months and a response rate of original articles Annals of Oncology 15%-35% in metastatic soft tissue sarcoma whatever the histological subtypes [24] . Sarcoma experts consider that doxorubicin or doxorubicin-based regimens should be considered as front-line in patients with advanced or metastatic angiosarcoma. Nevertheless, angiosarcomas are not usually individualized in a large database [22, 25] and the evidences are limited. In our experience, doxorubicin-based regimens provide a response rate of 31% and a median progression-free survival of 5.9 months. These results are concordant with literature data [6, 7] . For example, Fury et al. [6] report that the median progression-free survival is 3.7 months with doxorubicin alone (12 patients) and 5.4 months with doxorubicin plus ifosfamide combination (7 patients). Fayette et al. [7] report that doxorubicin-or ifosfamide-based regimens provide objective response in 7 out of 17 assessable patients (26%).
The use of weekly paclitaxel as treatment of advanced or metastatic angiosarcoma is relatively recent. Fata et al. [17, 19] had first reported that 8 out of 9 patients suffering from scalp angiosarcoma achieved a partial response with paclitaxel (175 mg/m 2 per 3 weeks). The median progression-free survival was 5 months. Schlemmer et al. [18] had reported the European Organization for Research and Treatment of Cancer experience with paclitaxel in patients with metastatic angiosarcoma. Different schedules had been used (3-week and weekly regimens). The overall response rate was 20/32 with 1 complete response. The median progression-free survival was 7.6 months. The Annals of Oncology original articles response rate was 6/8 in patients with scalp and skin angiosarcomas compared with 14/24 cases in patients with other primary locations [18] . The activity of weekly paclitaxel in angiosarcoma had been confirmed by a phase II trial assessing the efficacy of the weekly paclitaxel regimen (80 mg/m 2 d1, d8, d15, 21-day-cycle) has been confirmed by a phase II trail [20] . The response rate is 20%; but the nonprogression rate is 75% at 3 months and 24% at 6 months. The activity is quite similar in chemotherapy-naive patients and pretreated patients. This is a specific characteristic of angiosarcoma since taxanes are clearly ineffective for other histological subtypes of soft tissue sarcoma [26] [27] [28] . In the present report, weekly paclitaxel provides a response rate of 45.5% and a median progression survival of 5.6 months. Some hypothesize that this activity could be due to the 'antiangiogenic properties' of weekly paclitaxel.
This study points out the role of metastasectomy after first-line chemotherapy. In the previous phase II trial, we have already noticed that three patients with aggressive and locally advanced angiosarcoma receiving weekly paclitaxel experienced a clear tumor-growing stop in allowing a large en bloc resection. In two cases, there is no viable residual cell and in the third case, the remaining tumor displays <5% of identifiable residual cells [20] . In the present series, eight patients underwent metastasectomy, mainly for skin and soft tissue metastasis but also for visceral metastasis (liver and lung). Several reports have shown promising results and prolonged survival after surgical treatment of metastases from soft tissue sarcoma whatever the histological subtypes [29] [30] [31] [32] . After resection of metastasis, the reported 5-year survival is 15%-25%, exceeding the outcome observed under chemotherapy [5, [29] [30] [31] [32] [33] . Nevertheless, it is hard to discriminate the respective roles of the surgical procedure itself and the selection process of patients undergoing to curative-intent metastasectomy that retains patients with good performance status, without underlying comorbid conditions, with normal cardiac and pulmonary functions, etc. Establishing the real benefit of metastasectomy would require theoretically a formal randomized clinical trial with stratification according to the main prognostic factors (such as grade). But for this question, a randomized phase III trial appears hardly feasible. The present analysis suggests that metastatic angiosarcoma amenable to surgery have had better prognosis, but we ignore if this was the consequence of the surgery or the selection of less aggressive forms of metastatic angiosarcoma. Moreover, only eight patients underwent surgery, so the figures must be considered with caution.
This retrospective study presents the limitations due to its retrospective nature. For example, the grade and the biological parameters (LDH, albumin, hemoglobin .) are missing in 33%-50% of cases. This did not allow introducing biological parameters in the final multivariate model. Moreover, the relatively limited number of cases receiving doxorubicin-based regimens and weekly paclitaxel did not allow identifying of predictive factors for both regimens. We did not collect the administered second-line treatment that could influence the outcome. Nevertheless, this series is the largest published until now.
Regarding these findings, weekly paclitaxel and doxorubicinbased regimens are two valuable options for treating metastatic angiosarcoma. In practice, the choice depends on prior exposure to anthracycline (e.g. for prior treatment of breast cancer or lymphoma) and underlying comorbid conditions (such as chronic heart failure). Other regimens do not provide outcome advantage compared with palliative care. If possible, metastasectomy should be considered.
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